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Heart Rhythm Monitoring Strategies for Cryptogenic Stroke:
2015 Diagnostics and Monitoring Stroke Focus Group Report
Gregory W. Albers, MD; Richard A. Bernstein, MD, PhD; Johannes Brachmann, MD; John Camm, MD; J. Donald Easton, MD;
Peter Fromm, MPH, RN; Shinya Goto, MD, PhD; Christopher B. Granger, MD; Stefan H. Hohnloser, MD; Elaine Hylek, MD;
Amir K. Jaffer, MD, MBA; Derk W. Krieger, MD, PhD; Rod Passman, MD, MSCE; Jesse M. Pines, MD, MBA, MSCE; Shelby D. Reed, PhD;
Peter M. Rothwell, MD, PhD; Peter R. Kowey, MD

S

troke is a major public health issue worldwide. The
prevalence of stroke in 2010 was 33 million, with
16.9 million people having a ﬁrst stroke.1 Stroke was the
second-leading cause of death behind heart disease globally,
accounting for over 10% of total deaths worldwide.1
Stroke is a heterogeneous condition that can be due to
rupture of a blood vessel (hemorrhagic) or to blockage of a
vessel (ischemic). About 85% of strokes are ischemic in origin
and these are often classiﬁed by mechanism.2 This should be
distinguished from risk factors such as hypertension, diabetes, smoking, etc. Risk factors increase the risk of stroke
but do not necessarily explain the mechanism of a particular
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stroke. About 25% of ischemic strokes have a radiographic
appearance similar to that seen in patients with cardioembolic
sources (such as atrial ﬁbrillation [AF], prosthetic valves,
valvular prolapse, or mitral valve regurgitation), but no embolic
source is found. These “cryptogenic strokes” (CS; also called
embolic strokes of undetermined source)3 pose a particular
clinical challenge in that the optimal antithrombotic therapy to
reduce recurrence is uncertain. Since there are currently no
data to support long-term oral anticoagulation (OAC) in CS,
but also no speciﬁc trials that have addressed this question,
guidelines recommend antiplatelet therapy. Identiﬁcation of
AF in these patients changes the most likely mechanism to
cardioembolism, and thus changes the recommended
antithrombotic therapy to OAC, which is extremely effective
in preventing stroke in patients with AF.
This report is based on discussions held at The Diagnostics
and Monitoring Stroke Focus Group, a meeting held on
January 15 to 17, 2015. The meeting focused on CS as a
healthcare issue, and the utility of extended cardiac monitoring for AF in patients with strokes of unknown origin. The
objectives of the meeting were to review existing information
on the subject, deﬁne areas where knowledge was lacking or
limited, and discuss study designs by which information gaps
might be ﬁlled.

Stroke: A Major Public Health Concern
In the United States alone, 800 000 people have a stroke
each year and nearly 130 000 die, making it the ﬁfth leading
cause of death overall and the leading cause of serious
disability in adults.1 In fact, most older adults fear disabling
stroke more than they fear death itself.4 At 6 months
following a stroke, 50% of patients have remaining hemiparesis, 30% are unable to walk without assistance, 46% have
cognitive deﬁcits, 35% have depressive symptoms, 19% have
aphasia, 26% are dependent on others for activities of daily
living, and 26% are institutionalized in a nursing home.4
Overall, the direct and indirect cost of stroke in 2010 in the
United States was $36.5 billion; the mean-per-person lifetime
Journal of the American Heart Association
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Arriving at a Diagnosis of Cryptogenic Stroke
The TOAST (Trial of ORG 10172 in Acute Stroke Treatment)
criteria, which is the most commonly used classiﬁcation
scheme in clinical practice, deﬁne CS as brain infarction that
is not attributable to a deﬁnite cardioembolism, large artery
atherosclerosis, or small artery disease despite extensive
vascular, cardiac, and serologic evaluation.2 Note that the
TOAST classiﬁcation includes ≥2 equally plausible etiologies
under the classiﬁcation of undetermined etiology. Inter-rater
agreement is poor for strokes of unknown cause using the
TOAST criteria.6
CS is a diagnosis of exclusion. Thus, as diagnostic modalities
improve, the percentage of strokes classiﬁed as cryptogenic
should decrease. Furthermore, it is clear that the pathway
leading to a diagnosis of CS can be variable depending on the
extent of diagnostic evaluation. In the CRYSTAL-AF study,7
stroke was classiﬁed as cryptogenic after extensive testing—
including 12-lead electrocardiography (ECG), ≥24 hours of ECG
monitoring, transesophageal echocardiography, screening for
thrombophilic states (in patients <55 years of age), and
magnetic resonance angiography, computed tomographic
angiography, or catheter angiography of the head and neck—
did not reveal a plausible stroke mechanism. In addition,
magnetic resonance imaging or computed tomography had to
show a lesion consistent with symptoms, thus excluding
transient ischemic attack based on the most current tissuebased deﬁnition.8 Lacunar stroke was also excluded (deﬁned as
a single acute ischemic lesion <1 cm in diameter occurring in a
territory of a small penetrating artery in the basal ganglia,
internal capsule, corona radiate, or thalamus).
The categorization of an individual case of stroke as
“cryptogenic” will vary signiﬁcantly depending on the care
setting and the extent of the diagnostic evaluation. Thus, the
DOI: 10.1161/JAHA.115.002944

percentage of strokes classiﬁed as cryptogenic is likely to be
higher in routine healthcare settings than in clinical trials.

Implications of Stroke Subtype for
Antithrombotic Therapy
Patients with cardioembolic stroke are typically treated with
oral anticoagulants for long-term secondary prevention,
although this is only formally established in AF and in some
patients with valvular prosthesis. Antiplatelet agents are
recommended for patients with large artery atherosclerosis or
small artery disease. Antithrombotic agents are generally
avoided, both acutely and for long-term secondary prevention,
in patients who sustained a primary intracerebral hemorrhage.
Primary intracranial hemorrhages must be differentiated from
hemorrhagic transformation of an ischemic stroke. Hemorrhagic transformation of ischemic stroke is very common in
cerebral embolism and the vast majority of these transformations are asymptomatic because they represent bleeding
into nonviable ischemic core tissue. Hemorrhagic transformation of an ischemic stroke is not a predictor of future
primary intracerebral hemorrhages and therefore does not
represent a contraindication to antithrombotic therapy.
Primary intracranial hemorrhages may also permit anticoagulation in selected cases, although prospective data are
missing.

The Contribution of AF to Risk for Stroke
The risk for stroke or thrombotic embolism is increased about
5-fold in patients with AF.9 However, since AF is frequently
asymptomatic10 and occurs sporadically, it can be difﬁcult to
detect with traditional intermittent monitoring techniques and
establish a relationship between stroke and AF paroxysms.11,12 Recent data from devices capable of continuous
arrhythmia monitoring suggest that even brief episodes of AF
increase the risk of stroke, although the precise amount of AF
needed to elevate stroke risk is controversial, as is the causal
relationship between AF and stroke. These studies have
employed various AF thresholds to dichotomize cohorts into
groups with “low” and “high” AF burden. Such thresholds
were often arbitrary and based either on the technical
limitations of the devices used in the study or median values
resulting from the particular population studied in order to
divide the cohorts into equal sample sizes for the purpose of
maximizing statistical power. Regardless, these studies have
been consistent in showing that relatively brief amounts of
device-detected AF are required to elevate stroke risk among
patients primarily without a prior history of stroke or transient
ischemic attack. In the Mode Selection Trial (MOST), atrial
high-rate episodes lasting ≥5 minutes, as detected by paceJournal of the American Heart Association
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incremental cost of ischemic stroke is estimated at
$140 048. Of note, between 2012 and 2030, the total direct
medical stroke-related costs are projected to triple from
$71.6 to $184 billion.4 Indeed, the problem is even worse in
Asian countries, where the incidence of stroke is greater than
that of myocardial infarction.5
Large-artery atherosclerotic stenoses and small-artery
disease account for about 50% of ischemic strokes overall.
A further 20% result from a major-risk cardiac source, such as
AF, valve lesions, or left ventricular thrombus, and 5% are
attributed to unusual causes, such as thrombophilic disorders
or vasculitis.3 The remaining one quarter are CS: nonlacunar
strokes (eg, embolic appearing) without an identiﬁed cardioembolic source, and with no evidence of hemodynamically
signiﬁcant atherosclerosis in the arteries proximal to the
stroke.3 It is estimated that about 200 000 CS occur in the
United States annually.
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unexpected that the majority of strokes were not preceded
by AF in these largely non-AF populations. In contrast, a
recent analysis of patients from the Veterans Administration
has shown that, among patients with device-documented AF,
the presence of relatively brief amounts of AF raised the
short-term risk of stroke 4- to 5-fold.16 This risk was highest
in the initial 5 to 10 days following the episode of AF and
rapidly declined after longer periods. Importantly, this
analysis had more strokes than TRENDS, ASSERT, and
IMPACT combined, increasing the ability to infer a temporal
relationship. These ﬁndings indicate that a temporal relationship between AF and stroke may indeed exist and that
the mechanism of stroke for patients with more frequent or
long-lasting AF also applies to populations with lower
burdens of AF detected by implanted devices. By all means,
patients with AF have abundant stroke risk factors and
therefore other causations than cardiac embolism may be at
play.

Detecting AF in the Cryptogenic Stroke
Patient: Available Technologies
The advent of intermediate-term external monitors and
insertable AF-sensitive diagnostic devices has dramatically
improved our ability to detect brief, rare episodes of AF in
patients with stroke. Additionally, AF-sensitive cardiac
implantable electronic devices have also contributed to
uncovering undiagnosed AF in patients with or without a
history of CS, and with subsequent stroke events.
External monitoring systems are viable methods for
detecting AF over the course of a few days to several weeks.
A number of different technologies have been developed for
such monitoring. Holter monitors are, by far, the most widely
used diagnostic tool for monitoring, and have extensive
evidence supporting their use for short- to intermediate-term
monitoring. These devices—currently about 110970930
mm, or the size of a deck of cards—are clipped to the
patient’s belt or carried in a pocket. Electrodes are afﬁxed
using adhesive patches.
Ambulatory event monitors provide noncontinuous monitoring and are typically used until the patient experiences
symptoms or up to 1 month.19 These recording devices may
be worn continuously and activated only when the patient
experiences symptoms. Recorded ECGs are either stored for
analysis or transmitted to a receiving station for assessment.
Patch systems have been developed that provide intermediate-term continuous monitoring analogous to a Holter
monitor, recording and storing information for longer time
periods.19 These devices consist of a patch worn over the left
pectoral region of the body that records continuously for
≤14 days while the patient keeps a symptom log. At the end
of the recording period, the patient mails back the recorder in
Journal of the American Heart Association
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maker, were associated with a 5.9-fold increased risk for
clinically manifest AF, and a 2.8-fold increased risk for the
composite of stroke and death.13 In the more recent ASSERT
study, which enrolled patients aged ≥65 years with hypertension and no history of AF in whom a pacemaker or
deﬁbrillator had been recently implanted (N=2580), subclinical atrial tachyarrhythmias (deﬁned as episodes of atrial rate
>190 beats/minute for >6 minutes) were seen in 10.1% of
patients by 3 months of follow-up. During subsequent longterm follow-up, these initial episodes of subclinical AF were
associated with a 5.6-fold increase in risk for clinical AF and a
2.5-fold increase in risk for ischemic stroke or systemic
embolism.14 Since studies have shown that the AF threshold
required for elevating stroke risk may be a function of
additional stroke risk factors,15 patients with prior stroke are
likely to be at increased risk of recurrent stroke with even
lower AF thresholds than reported for primary stroke prevention.
An analysis of data from the CRYSTAL AF study showed
that 97% of patients with insertable cardiac monitors and AF
detected by 12 months were prescribed OAC employing an
AF detection threshold of only 2 minutes,7 suggesting that
physicians were particularly sensitive to brief episodes among
patients who have experienced a prior CS. At 12 months, the
median time to AF detection was 84 days.
The issue of whether a temporal relationship exists
between episodes of AF and the occurrence of stroke
continues.16 The TRENDS trial included 2486 patients with
an indication for a pacemaker or a cardioverter–deﬁbrillator,
at least 1 stroke risk factor, and ≥30 days of available device
data.17 A subgroup analysis of the TRENDS study included 40
patients (1.6%) who experienced an ischemic stroke during
the trial; half of these patients with stroke had ≥1 episode of
atrial tachyarrhythmias or atrial ﬁbrillation (AT/AF) detected
prior to the event. Notably, the duration of pre-event
monitoring was considerably shorter in patients who did not
have any episodes of atrial tachyarrhythmias or atrial
ﬁbrillation detected prior to the thromboembolic event;
furthermore, 6 of the remaining 20 patients had detected
AF prior to the event with short episodes of atrial tachyarrhythmias or atrial ﬁbrillation that did not reach the 5minute threshold prespeciﬁed by the study to constitute
“device-detected” atrial tachyarrhythmias or atrial ﬁbrillation.
A different subanalysis based on the ASSERT study,18 showed
that, among patients who experienced an embolic event after
3 months of follow-up (mean follow-up was 2.5 years),
device-detected AF occurred prior to the event in about one
third of cases and occurred within 30 days before the event in
fewer than 10% of cases. However, it is important to note that
only 20% of patients in the TRENDS study had a history of AF,
and patients with a prior history of AF were excluded from
enrollment in the ASSERT study. Therefore, it is not
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the context of a clinical trial, compliance with prolonged
external monitoring regimens can be less than 50%.21
Insertable cardiac monitors represent the most sensitive
method for detecting infrequent episodes of AF. These
devices automatically detect AF and other abnormal cardiac
rhythms, such as bradycardia, asystole, and ventricular
tachycardia over the course of months to years, rather than
weeks. Patients with infrequent episodes are unlikely to be
missed using this long-term monitoring strategy. The new
generation of devices automatically detects cardiac events
and transmits them on a daily basis for review by the clinician.
Additionally, representative ECG strips of these automatically
detected episodes are stored in the device to allow conﬁrmation of the rhythm. Patients can also activate ECG
recordings while experiencing symptoms so that the physician
can determine if there is an association with a cardiac event.
Other diagnostic information, such as daily AF burden,
ventricular rate during AF, day/night heart rate, heart rate
variability, patient activity, and histogram information stored
between device interrogations for AF episode start time and
AF episode duration are also available to the physician. This
new generation of devices uses an AF detection algorithm
based on R-R intervals; in addition, p-wave information (if

Table 1. Advantages and Disadvantages of Available Monitoring Technologies
Monitoring Technology

Advantages

Disadvantages

24-hour Holter monitoring

1 Inexpensive

1 Likely to miss most PAF
2 External leads

Extended Holter monitoring /
ambulatory event monitors

1 Inexpensive

1 Depending on duration of monitoring, likely to miss
a significant fraction of PAF
2 External leads
3 Poor patient compliance that may decline rapidly
with increased monitoring durations

Patch monitors

1 Continuous intermediate-term monitoring is possible
2 Minimally obtrusive for an external device
3 Well tolerated

1 Relatively more expensive
2 Depending on duration of monitoring, likely to miss
a significant fraction of PAF
3 Extended monitoring may require ≥1 patch

Mobile cardiac telemetry

1 Continuous intermediate-term monitoring is possible
2 Rapid response to developing clinical situations

1 Relatively more expensive
2 Long-term monitoring incurs costs
3 Relies on external leads and may be associated
with poor patient compliance

Insertable cardiac monitors

1
2
3
4
5

1 Need for minor invasive procedure
2 Need to define long-term pathways for data
analysis and management
3 Most expensive (cost of device and implantation/
retrieval procedures)
4 Long-term monitoring incurs costs

No external wires
100% compliance
Patient convenience
Provides long-term continuous monitoring (3 years)
Rapid response to developing clinical situations

PAF indicates paroxysmal atrial ﬁbrillation.

DOI: 10.1161/JAHA.115.002944
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a prepaid envelope to a central station, and a full report is
provided to the physician within a few days.
Real-time continuous attended cardiac monitoring systems
(mobile real-time cardiac telemetry systems, or MCOT—
Mobile Cardiac Outpatient Telemetry) are the newest modality
for external event monitoring.20 These devices are worn
continuously and automatically record and transmit rhythm
data from ambulatory patients to a monitoring center.
Symptoms may be correlated to arrhythmias through
patient-triggered activation. Cardiac activity is monitored
continuously through chest electrodes that are attached to a
pager-sized sensor, which transmits collected data to a
portable monitor with a built-in cell phone. Data are transmitted and analyzed promptly by technicians who can contact
the patient and/or the physician if an urgent intervention is
needed.20
The technologies described above have several limitations
(Table 1). First, intermittent or short- to intermediate-term
monitoring of a disease state that is itself intermittent
increases the risk that AF will not be detected, relative to
longer-term monitoring. Second, extended duration of external monitoring improves the probability of detection of AF, but
comes at the cost of decreased patient compliance—even in
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the Amplatzer cardiac plug.26,27 However, these procedures
are associated with complications and further study is
required to show their usefulness in poststroke populations.
Second, concerns over the relative invasiveness of these
technologies have been addressed, at least in part, by the
decreasing size and ease of implant of insertable cardiac
monitors. However, these devices still require an invasive
procedure and incur procedural costs as well as ongoing
monitoring costs. Third, these devices produce large amounts
of potentially clinically relevant data over the long term. Very
important questions remain regarding who is responsible for
reviewing and interpreting the data, avoiding “data overload,”
and transitioning responsibility for the device among healthcare providers.

Modalities for Monitoring AF in Cryptogenic
Stroke Patients: Review of the Literature
Observational studies suggest that clinicians frequently fail to
detect paroxysmal AF as a cause of ischemic stroke.28 Yet
guidelines remain nebulous in their recommendations for
extended monitoring, in part because few large, prospective,
well-designed studies are available on which to base highquality recommendations.
It is unsurprising—given the intermittent nature of paroxysmal AF—that in CS patients, the longer durations of
monitoring have a higher yield for detecting AF.17,29 In CS
patients monitored via external devices, AF detection yields
have ranged from 3.2% for 24-hour Holter monitors at

Table 2. AF Detection With External Cardiac Monitoring in CS Patients
Citation

Number of Patients

AF Deﬁnition

Monitoring Duration

AF Detection Yield

Monitoring Type

Tayal et al32

56

<30 s

21 days

18%

MCOT

>30 s
Elijovich et al

33

Gaillard et al34
Bhatt et al
Flint et al

31

35

5%

20

N/A

30 days

20%

Event Monitor

98

32 s

30 days

9%

Transtelephonic monitoring

62

30 s

28 days

24%

MCOT

236

≤30 s

30 days

4%

MCOT

>30 s
Kamel et al36
Miller et al

37

20
156

7%

30 s

21 days

0%

MCOT

<30 s

30 days

12%

MCOT

≥30 s
EMBRACE30

572

30 s

2.5 min

5%
30 days

16.1%

Event Monitor

24 h

3.2%

Holter

30 days

9.9%

Event Monitor

24 h

2.5%

Holter

AF indicates atrial ﬁbrillation; CS, cryptogenic stroke; MCOT, mobile cardiac outpatient telemetry; N/A, not available.
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adequately detected) is used to improve the sensitivity of the
algorithm by reducing the number of inappropriate AF episode
detections seen in earlier devices.22,23 Even though p-waves
can be difﬁcult to detect in some patients, this feature does
not affect the ability of the algorithm to identify patients who
are having AF, and has the clinical impact of reducing
physician review burden.22,23 The new monitors are smaller
(794594 mm in size, approximately one third the width of an
AAA battery), they are inserted with a minor invasive
procedure, and provide continuous monitoring for up to
3 years.
As with external monitoring, insertable cardiac monitors
have limitations (Table 1). First—and perhaps foremost in
today’s healthcare environment—these devices are expensive, especially when compared with simple 24-hour Holter
monitoring. In order for these devices to be economically
justiﬁed, there must be clear pathways in place so that the
only patients who receive an insertable cardiac monitor are
those in whom it is clinically justiﬁed. This means not only
excluding patients in whom AF is highly unlikely to have
contributed to the stroke, but also patients in whom a ﬁnding
of AF would most likely not result in care change. Admittedly,
these contraindications will become more relative than
absolute with the evolution of technology to treat AF more
effectively, and to mechanically exclude the left atrial
appendage. Left atrial appendage exclusion is a means of
preventing thrombus formation in the appendage and subsequent thromboembolic events in these patients. Existing left
atrial appendage exclusion alternatives include surgery and
devices such as the WATCHMAN device,24 the Lariat,25 and
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lasting ≥30 s in 16.1% of the intervention group, compared
with 3.2% of the control group, yielding an absolute difference
of 12.9 percentage points (95% CI, 8.0 to 17.6; P<0.001). AF
lasting ≥2.5 minutes (a secondary end point) was present in
9.9% of patients in the intervention group, as compared with
2.5% of the control group (absolute difference, 7.4 percentage
points; 95% CI, 3.4 to 11.3; P<0.001). As expected, the
majority of patients were receiving antiplatelet therapy at
randomization. By 90 days, OAC therapy had been prescribed
to more patients in the intervention group (18.6%) as
compared with the control group (11.1%; P<0.01).
The CRYSTAL AF study provides additional evidence that
AF is a common ﬁnding in patients with CS.7 This controlled
study enrolled 441 patients who were randomized in a 1:1
ratio to insertable cardiac monitoring versus standard
arrhythmia monitoring (based on local practice). Patients
were ≥40 years old and resulted in a substantially younger
population (mean age 6111 years) than that enrolled in the
EMBRACE study (mean age 739 years). Furthermore, all
patients in this study underwent transesophageal echocardiography to exclude a cardioembolic source for the initial
stroke. Patients were required to have no evidence of AF
during ≥24 hours of ECG monitoring and underwent randomization within 90 days of the index event to either an
insertable cardiac monitor or conventional follow-up, which
consisted of assessments at scheduled and unscheduled
visits, with ECG monitoring performed at the discretion of the
site investigator. The primary end point was time to ﬁrst
detection of AF lasting >30 s within 6 months; secondary end
points included, but were not limited to, time to ﬁrst detection
of AF within 12 months. At 6 months, AF was detected in
8.9% of patients in the insertable cardiac monitor group,
compared with 1.4% of patients in the routine care group
(hazard ratio, 6.4; 95% CI 1.9–21.7; P<0.001). The median
time from randomization to detection of AF was 41 days in
the insertable cardiac monitor group and 32 days in the

Table 3. AF Detection With Insertable Cardiac Monitors in CS Patients
Citation

Cotter et al38
Ritter et al

39

Etgen et al

40

Rojo-Martinez et al

41

SURPRISE42
CRYSTAL-AF

7

Number of
Patients

AF Deﬁnition
(min)

Monitoring
Duration

AF Detection
Yield

51

2

229116 days

25.5%

60

2

1 year

16.7%

22

6

1 year

27.3%

101

2

281212 days

33.7%

85

2

569310 days

16.1%

221

2*

≥6 months

8.9% at 6 months
12.4% at 12 months
30.0% at 36 months

AF indicates atrial ﬁbrillation; CS, cryptogenic stroke.
*Thirty seconds in the control arm.

DOI: 10.1161/JAHA.115.002944
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90 days in the control arm of the EMBRACE study30 to 24%
overall in 1 study using MCOT for 28 days (Table 2).31
However, it is important to note that the vast majority of
episodes in this MCOT study were very brief in duration and
the AF yield for episodes longer than 5 minutes was only 9%.
A number of studies have evaluated the AF detection yield
in patients with insertable cardiac monitors.29 A summary of
these studies is presented in Table 3. The variation in AF
detection yields between the different studies is likely due to
differences in patient populations, variability in comprehensiveness of poststroke workups, monitoring durations, age,
and the deﬁnition of AF with regard to episode duration.
Two prospective, randomized trials with different study
designs, which enrolled different populations of patients with
CS, provide evidence that prolonged monitoring of CS
patients detects paroxysmal AF that goes undiagnosed with
standard monitoring techniques.7,30
The ﬁrst study, EMBRACE, enrolled 572 patients aged
≥55 years, without known AF, and with an ischemic stroke or
transient ischemic attack of undetermined origin (according
to TOAST criteria) within the previous 6 months.30 Patients
were placed in the CS category after a workup that included a
12-lead ECG, ambulatory ECG monitoring with a Holter
monitor for ≥24 hours, brain and neurovascular imaging,
and echocardiography. Patients were excluded if the most
likely etiology of stroke had already been determined (eg,
large- or small-vessel disease or other known cause). Patients
were randomly allocated to 1 of 2 groups: The intervention
group underwent ECG monitoring with a 30-day eventtriggered loop recorder, while the control group underwent
1 additional round of 24-hour Holter monitoring. The primary
outcome was the detection of ≥1 episode of ECG-documented
AF or ﬂutter lasting ≥30 s within 90 days of randomization.
Secondary outcomes included the use of OACs at 90 days.
Eighty percent of patients receiving a loop recorder completed
≥3 weeks of monitoring. Extended monitoring detected AF
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Clinical and Economic Evidence Gaps for
Monitoring AF in Cryptogenic Stroke Patients
What Is the Appropriate Duration of Monitoring?
A number of factors inﬂuence the rate of AF detection in CS
patients and relate to the length of monitoring, the AF
DOI: 10.1161/JAHA.115.002944

duration deﬁnition employed, the time interval from the initial
stroke to the start of monitoring, and patient characteristics.
The data summarized above clearly indicate that longer
durations of cardiac monitoring are associated with increased
yield relative to shorter periods of cardiac monitoring. These
ﬁndings have implications for type of secondary prevention
therapies and, potentially, downstream outcomes. Data from
existing studies indicate that monitoring between 1 month
and up to 3 years detects increased AF beyond standard
techniques.
In this panel’s opinion, our general recommendation is for
at least 30 days of monitoring; if the results are negative,
longer term monitoring with an insertable cardiac monitor is a
reasonable consideration. This recommendation is based on
several facts. In the CRYSTAL AF study,7 if monitoring had
stopped at 30 days as recommended in the current guidelines, most AF would have been missed, given that the median
time from randomization to AF detection was 84 days
(interquartile range, 18–265) at 12 months. Furthermore,
several studies using insertable cardiac monitors to monitor
CS patients have also shown average times to diagnosis
longer than 30 days and ranging from 41 to 152 days
(Table 3).7,38–43 Future research should characterize the time
course for AF detection post-CS and the progression of AF
over time.

Which Patients With Cryptogenic Stroke Should
Be Monitored for AF?
Current guidelines for patients who have experienced an
ischemic stroke without an apparent cause recommend that
prolonged rhythm monitoring (30 days) for AF is reasonable
within 6 months of the index event.44 The accumulating
evidence with longer monitoring durations such as those
employed in the CRYSTAL AF study indicate that monitoring
periods beyond 30 days result in greater yield. Additional data
are required to clarify whether patients should follow a
sequential approach to monitoring (eg, 30 days of monitoring
with an external diagnostic and if negative, long-term
monitoring with an insertable cardiac monitor) or early
initiation of long-term monitoring. However, it is clear that
CS patients should undergo extended rhythm monitoring to
identify AF. Actual recommendations will need to be based on
several factors, including patient and payment issues pending
adequately powered studies that provide deﬁnitive conclusions.

How Much AF Warrants Anticoagulation?
As discussed above, AF is an important risk factor for stroke.
Questions remain, however, on how much AF should trigger
the decision to anticoagulate for secondary stroke prevention
Journal of the American Heart Association

Downloaded from http://jaha.ahajournals.org/ at George Washington University on March 29, 2016

7

SPECIAL REPORT

control group. AF was asymptomatic in 14 of 19 ﬁrst episodes
in the insertable cardiac monitor group (74%) and in 1 of 3
ﬁrst episodes in the control group (33%). By 12 months, AF
had been detected in 12.4% of patients in the implantable
cardiac monitor group compared with 2.0% of patients in the
control group (hazard ratio 7.3; 95% CI 2.6–20.8; P<0.001). At
12 months, 121 ECGs, 32 24-hour Holter monitors, and 1
event recorder were required to ﬁnd AF in 4 patients in the
control group. Ischemic stroke or transient ischemic attack
occurred in 5.2% of patients in the insertable cardiac monitor
group, compared with 8.6% of those in the control group
during the ﬁrst 6 months after randomization.
Despite that the numbers are small, the presence or
absence of an insertable cardiac monitor appeared to
inﬂuence the rate of OAC use. In the insertable cardiac
monitor group, 10.1% of patients received an anticoagulant
(even though prescription of anticoagulants was not mandated by the study protocol), as compared with 4.6% of the
control group at 6 months (P=0.04), and 14.7% versus 6.0% of
the groups, respectively, at 12 months (P=0.007). Overall at
12 months, 97% of patients in whom AF had been detected
were receiving OACs. Although not all patients were followed
beyond 12 months (81% of patients were followed for more
than 12 months), the rate of detection of AF at 36 months
was 30% in the insertable cardiac monitor group compared
with only 3% of patients in the control group.
These studies showed that continuous, long-term monitoring increased the diagnostic yield regardless of the age of the
patients. However, absolute rates of AF increased with age,
which is likely to explain the higher yield of monitoring relative
to its duration in EMBRACE. Other factors such as the rigor of
the stroke workup (use of transesophageal echocardiography,
vascular imaging, and pre-enrollment monitoring) also likely
inﬂuence the reported AF detection rates and precludes a
direct comparison between the 2 studies. Neither the
EMBRACE nor the CRYSTAL AF study evaluated the impact
of monitoring strategies on hard clinical outcomes, including
recurrent stroke. Nevertheless, CRYSTAL AF showed that
long-term monitoring has the potential to signiﬁcantly change
the treatment strategies offered to the patient. Based on the
results of these studies, an editorial published in the New
England Journal of Medicine suggested that prolonged monitoring of heart rhythm should become the standard of care
for patients with CS.28
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What Are the Appropriate Pathways for Use of
Insertable Cardiac Monitors?
The results of the CRYSTAL AF study illustrate the potential
value of long-term monitoring with insertable cardiac monitors
DOI: 10.1161/JAHA.115.002944

in patients with CS. However, as noted previously, these
devices are costly and associated with a minor invasive
procedure. From an economic perspective, it is important to
appropriately deﬁne the time horizon so that all downstream
costs and health consequences are captured. Therefore, both
the economic and clinical beneﬁts should be considered. The
economic value of insertable cardiac monitors must be further
explored to ensure appropriate targeting of healthcare
resources. From a clinical perspective, it is critical that the
patients who can beneﬁt from such monitoring—those in
whom the data generated by the device have the potential to
change downstream care—are clearly deﬁned. Any diagnostic
pathway should provide recommendations based on the best
available evidence for every time point in their care continuum, beginning at hospital admission to discharge, and for
long-term surveillance. Furthermore, pathways should identify
healthcare providers responsible for the analysis of device
data, both immediately after insertion and over the long term,
as well as appropriate actions to take when device data show
evidence of AF.

Will Long-Term Monitoring for AF in Cryptogenic
Stroke Patients Impact Hard Outcomes?
The most important question with any intervention is whether
it will have an impact on meaningful, clinically relevant
outcomes. To date, long-term monitoring studies have not
been powered to demonstrate that increased AF detection
through extended monitoring results in reduced recurrent
stroke rates and/or systemic embolism. A prospective study
evaluating the impact of traditional monitoring compared to
long-term continuous monitoring on time to ﬁrst event
(stroke, systemic embolism, major adverse cardiac events,
and cardiovascular death) would be informative but is
associated with several logistical (eg, size and cost of the
trial) and potential ethical challenges (randomizing patients to
an inferior monitoring strategy). In the interim, physicians will
need to rely on existing data and additional information from
ongoing trials and long-term registries to help inform the
question of clinical and economic outcomes.

Conclusions
CS is an important health issue leading to signiﬁcant
morbidity and diminished quality of life. As such, preventing
a second potentially further debilitating or fatal stroke is
paramount to inﬂuencing the outcomes of these patients. AF
is likely the cause for many recurrent strokes but goes
undetected due to the asymptomatic and intermittent nature
of the disease. The advent of several methods to monitor the
ECG longitudinally has increased our ability to identify AF in
these patients compared to traditional monitoring, but the
Journal of the American Heart Association
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in patients with CS. Currently, guidelines remain vague as to
the threshold of AF that warrants switching patients from antiplatelet agents to oral anticoagulants and the current practice
varies among experts. The thresholds used also depend on
whether the patient is being treated for primary or secondary
stroke prevention. Current recommendations are based on
literature demonstrating the value of oral anticoagulants in
reducing a ﬁrst stroke in patients with risk factors and
documented AF. While a number of studies have attempted to
identify the threshold of AF that places a patient at risk for an
initial stroke,14,15,45–48 only Botto et al15 have evaluated the
threshold linked to an increased risk of recurrent stroke
following the index event. In their study, patients presenting
with 5 minutes of AF were at an increased risk of stroke. In
the CRYSTAL AF study, 95% of the patients in the insertable
cardiac monitor arm who had AF had at least 1 day with
>6 minutes of AF. This resulted in use of oral anticoagulants
in 97% of patients with detected AF.7
What is clear is that device-detected AF is associated with
an increased thromboembolic risk and that patients who have
already experienced a stroke are at particularly high risk for
recurrent stroke. As all current risk assessment schema place
patients with AF in a high-risk category (2 points for stroke in
either CHADS2 or CHA2DS2-VASC),49–53 less emphasis has
been placed on the duration of AF required. Moreover, the
decision to anticoagulate is based on a number of variables,
including bleeding risk and other factors present in the
CHA2DS2-VASC score.
Several planned and ongoing trials will hopefully shed light
on these questions and increase our knowledge in other stroke
populations. ARTESIA (ClinicalTrials.gov, NCT01938248) will
evaluate the reduction in risk of primary stroke by OAC in
patients with subclinical AF and additional stroke factors.
STROKE-AF is a randomized study that will compare insertable
cardiac monitor versus standard of care in patients with
ischemic stroke of presumed known origin. The Reveal LINQ
Registry will collect real-world clinical data in patients using
insertable cardiac monitors, including CS patients. Future
studies evaluating large patient cohorts with CS and documented AF may help deﬁne this threshold; however, these data
will most likely not be available in the absence of a large
outcomes trial. Whether the mere detection of AF or a certain
threshold of AF duration is required for anticoagulation in this
patient population is not yet clear. For now, the authors
recommend a threshold of at least 2 to 6 minutes to enable
devices currently in use to capture an interpretable event.
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